MAP2K7 and metastatic melanoma: The first metastatic melanoma combination therapy consisted of the use of the BRAF vemafenib and dabrafenib inhibitors and the MEK cobimetinib and trametinib inhibitors, which have shown efficacy in the treatment of BRAFV600 mutation-positive or metastatic melanoma patients.